Differences

This shows you the differences between two versions of the page.

--- triaging_pdl1_3d_requests [2026/04/07 20:26] – gilbert
+++ triaging_pdl1_3d_requests [2026/04/07 20:40] (current) – removed gilbert
@@ Line 1: / Line 1: @@
-====== Biomarker Quick Reference List ======
-<WRAP info>
-; {{media:biomarkers:PDL1UPPERGIMARCH2026.pdf | ''PDL1UPPERGIMARCH2026''}}
-: PD-L1 IHC (22C3) — Gastric, GEJ, Esophageal Adenocarcinoma/ESCC.
-; {{media:biomarkers:BMCLAUDIN18.pdf | ''BMCLAUDIN18''}}
-: Claudin 18.2 IHC — Gastric or GEJ Adenocarcinoma.
-; {{media:biomarkers:PDL1HNSCC22C3PEMBRO.pdf | ''PDL1HNSCC22C3PEMBRO''}}
-: PD-L1 IHC (22C3) — Advanced HNSCC.
-; {{media:biomarkers:PDL1HNSCCNEOADPEMBRO.pdf | ''PDL1HNSCCNEOADPEMBRO''}}
-: PD-L1 IHC (22C3) — Resectable HNSCC (Neoadjuvant).
-; {{media:biomarkers:PDL1CERVIX.pdf | ''PDL1CERVIX''}}
-: PD-L1 IHC (22C3) — Cervical Cancer (SCC/Adeno).
-; {{media:biomarkers:MOLARCEP17.pdf | ''MOLARCEP17''}}
-: CEP17 SISH — Ploidy Analysis.
-; {{media:biomarkers:PDL1NSCLCPEMBRO22C3.pdf | ''PDL1NSCLCPEMBRO22C3''}}
-: PD-L1 IHC (22C3) — NSCLC Stage IIIb to IV.
-; {{media:biomarkers:PDL1NSCLCATEZOSP263.pdf | ''PDL1NSCLCATEZOSP263''}}
-: PD-L1 IHC (SP263) — NSCLC Stage II to IIIA (Adjuvant).
-; {{media:biomarkers:PDL1TNBC22C3PEMBRO.pdf | ''PDL1TNBC22C3PEMBRO''}}
-: PD-L1 IHC (22C3) — Triple Negative Breast Cancer (TNBC).
-</WRAP>
----
-====== Detailed Biomarker Tables ======
-===== Gastrointestinal Biomarkers =====
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | Gastric, GEJ, esophageal adenocarcinoma; ESCC | Pembrolizumab, Nivolumab | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1UPPERGIMARCH2026.pdf | ''PDL1UPPERGIMARCH2026''}} |
-| **Claudin 18.2** | Gastric or GEJ adenocarcinoma | Zolbetuximab | VENTANA CLDN18 (43-14A) %%RxDx%% | {{media:biomarkers:BMCLAUDIN18.pdf | ''BMCLAUDIN18''}} |
-</WRAP>
-===== Head & Neck Biomarkers =====
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | **Advanced** HNSCC | Pembrolizumab | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1HNSCC22C3PEMBRO.pdf | ''PDL1HNSCC22C3PEMBRO''}} |
-| **PD-L1** | **Resectable** HNSCC | Pembrolizumab as **Neoadjuvant** | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1HNSCCNEOADPEMBRO.pdf | ''PDL1HNSCCNEOADPEMBRO''}} |
-</WRAP>
-===== Gyne Biomarkers =====
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | Cervical cancer (SCC and Adeno) | Pembrolizumab | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1CERVIX.pdf | ''PDL1CERVIX''}} |
-| **CEP17 SISH** | Ploidy Analysis | N/A | VENTANA Inform Chrom. 17 | {{media:biomarkers:MOLARCEP17.pdf | ''MOLARCEP17''}} |
-</WRAP>
-===== Lung Biomarkers =====
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | NSCLC stage IIIb to IV | Pembrolizumab | PDL1 22C3 | {{media:biomarkers:PDL1NSCLCPEMBRO22C3.pdf | ''PDL1NSCLCPEMBRO22C3''}} |
-| **PD-L1** | NSCLC stage II to IIIA | Atezolizumab as **Adjuvant** | PDL1 SP263 | {{media:biomarkers:PDL1NSCLCATEZOSP263.pdf | ''PDL1NSCLCATEZOSP263''}} |
-</WRAP>
-===== Breast Biomarkers =====
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | TNBC | Pembrolizumab | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1TNBC22C3PEMBRO.pdf | ''PDL1TNBC22C3PEMBRO''}} |
-</WRAP>